Researchers from University of Gothenburg Report Recent Findings in Sezary Syndrome (Sezary Syndrome in West Sweden: Exploring Epidemiology, Clinical Features, and Treatment Patterns in a Registry-Based Retrospective Analysis).

A recent study conducted by researchers from the University of Gothenburg in Sweden explored the epidemiology, clinical features, and treatment patterns of Sezary syndrome (SS), a rare primary cutaneous T-cell lymphoma variant. The study found that SS remains incurable with a poor prognosis, and there is a need for personalized diagnostic approaches due to the variability in symptoms at diagnosis. The median survival for patients with SS was only 2.1 years, highlighting the aggressive nature of the disease. Combination therapy, specifically triple therapy involving retinoids, interferon alpha, and extracorporeal photopheresis (ECP), showed the longest median time to next treatment (TTNT). Early initiation of ECP treatment did not result in improved outcomes. The study emphasizes the importance of combination therapy and the need for further research to identify optimal treatment approaches. [Extracted from the article]